Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Beta Bionics, Inc.BBNX · Entity 2350 | Chief Financial Officer | September 02, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Beta Bionics, Inc.
Report date September 02, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 159,378 |
Reported balance
After 2026-09-02 transaction · row 1
1 source rowRow 1 · 2026-09-02 · Sale · Disposed 6,675 · Balance 159,378 F1: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. F2: The weighted average sale price for the transaction reported was $19.1131 and the range of prices were between $18.89 and $19.545. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.
F2: The weighted average sale price for the transaction reported was $19.1131 and the range of prices were between $18.89 and $19.545. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 31, 2025 Filed Feb 4, 2025 01:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantEmployee Stock Option (right to buy) · Derivative | 166,542 | $0.00 Strike: $7.51 | $0.00 |
DisclosureSEC source: 0001415889-25-002816 · form4-02032025_080204.xml · derivative · entry 1 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,542 Underlying: Common Stock · 166,542 shares Expires 2032-07-31 F1 · derivative.exercise_date: One-fourth of the shares subject to this option shall vest one year after August 1, 2022, and thereafter 1/36th of the shares subject to this option shall vest on each monthly anniversary thereof. F2 · derivative.underlying: Immediately prior to the closing of the initial public offering, each share of Class B Common Stock subject to this option was converted into an equal number of shares of Common Stock. Read SEC document |
| January 29, 2025 Filed Jan 31, 2025 21:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantEmployee Stock Option (right to buy) · Derivative | 186,203 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002479 · form4-01312025_090132.xml · derivative · entry 1 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,203 Underlying: Class B Common Stock · 186,203 shares Expires 2035-01-28 F1 · derivative.exercise_date: Vesting is monthly over a 48-month period starting January 29, 2025 in equal monthly amounts. F2 · derivative.underlying: Immediately prior to the closing of the initial public offering, each share of Class B Common Stock subject to this option was converted into an equal number of shares of Common Stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.